SCHEMBL1560465

SCHEMBL1560465

CC(C)Cn1cc(-c2cc3c(cn2)[nH]c2ncc(F)cc23)cn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 10/20 0.44
CHEK1 O14757 1/20 0.43
ACHE P22303 1/20 0.43
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
PDPK1 O15530 1/20 0.39
PIK3CA P42336 1/20 0.39
MAPK1 P28482 1/20 0.39
SYK P43405 1/20 0.37
MAPT P10636 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473684 0.82 CHEK1 (0.58) PIM1CHEK1ACHEMAPT
SCHEMBL1559819 0.81 CHEK1 (0.48) PIM1CHEK1ACHEMAPK1PRMT5
SCHEMBL1560912 0.79 CHEK1 (0.56) PIM1CHEK1ACHEPDPK1PIK3CA
SCHEMBL1559843 0.79 CHEK1 (0.47) PIM1CHEK1ACHEPIK3CAMAPK1
SCHEMBL1892804 0.77 CHEK1 (0.78) CHEK1ACHE
SCHEMBL2216275 0.70 PIM1 (0.46) PIM1CHEK1ACHEMAPK1MAPT
SCHEMBL16215705 0.70 CHEK1 (0.75) CHEK1ACHE
SCHEMBL12666733 0.69 CHEK1 (0.69) PIM1CHEK1ACHEMAPT
SCHEMBL1561318 0.69 NPC1 (0.39) CHEK1ACHEMAPT
SCHEMBL473697 0.69 CHEK1 (0.56) PIM1CHEK1ACHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178053-A1 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2011-07-21 US claimed
EP-2303882-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME Sanofi-Aventis (FR) 2011-04-06 EP claimed
WO-2009150381-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2009-12-17 WO claimed
US-20110178053-A1 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2011-07-21 US disclosed
EP-2303882-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME Sanofi-Aventis (FR) 2011-04-06 EP disclosed
WO-2009150381-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178053-A1 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME AOC3, CBR3, IDH3B PIM1 2969/4885CHEK1 786/4885ACHE 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.